Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, United Kingdom.
Department of Haematology, University of Cambridge, Cambridge, CB2 0PT, United Kingdom.
Nat Commun. 2018 Apr 12;9(1):1416. doi: 10.1038/s41467-018-03672-4.
Pulmonary arterial hypertension (PAH) is a rare disorder with a poor prognosis. Deleterious variation within components of the transforming growth factor-β pathway, particularly the bone morphogenetic protein type 2 receptor (BMPR2), underlies most heritable forms of PAH. To identify the missing heritability we perform whole-genome sequencing in 1038 PAH index cases and 6385 PAH-negative control subjects. Case-control analyses reveal significant overrepresentation of rare variants in ATP13A3, AQP1 and SOX17, and provide independent validation of a critical role for GDF2 in PAH. We demonstrate familial segregation of mutations in SOX17 and AQP1 with PAH. Mutations in GDF2, encoding a BMPR2 ligand, lead to reduced secretion from transfected cells. In addition, we identify pathogenic mutations in the majority of previously reported PAH genes, and provide evidence for further putative genes. Taken together these findings contribute new insights into the molecular basis of PAH and indicate unexplored pathways for therapeutic intervention.
肺动脉高压(PAH)是一种预后不良的罕见疾病。转化生长因子-β途径成分(尤其是骨形态发生蛋白型 2 受体 [BMPR2])中的有害变异是大多数遗传性 PAH 的基础。为了确定缺失的遗传率,我们对 1038 名 PAH 索引病例和 6385 名 PAH 阴性对照进行了全基因组测序。病例对照分析显示,ATP13A3、AQP1 和 SOX17 中的稀有变异明显过表达,并为 GDF2 在 PAH 中的关键作用提供了独立验证。我们证明了 SOX17 和 AQP1 突变与 PAH 的家族分离。编码 BMPR2 配体的 GDF2 基因突变导致转染细胞的分泌减少。此外,我们在大多数先前报道的 PAH 基因中发现了致病性突变,并提供了进一步潜在基因的证据。总之,这些发现为 PAH 的分子基础提供了新的见解,并表明了治疗干预的未探索途径。